! I’m your host today, Caroline Seymour.

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Takeda, we had the pleasure of speaking with Mikkael A. Sekeres, MD, professor of medicine and chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center of the University of Miami Health System, to discuss current clinical challenges and emerging treatments in myelodysplastic syndromes (MDS).

Potential combinations with pevonedistat, eprenetapopt (APR-246), venetoclax (Venclexta), or magrolimab, plus hypomethylating agents (HMAs) like azacitidine are being evaluated to determine whether they can improve upon the lackluster median survival for patients with higher-risk MDS (HR-MDS), explained Sekeres.

Sekeres added that although overall survival (OS) remains the gold-standard end point, trials are evolving to incorporate event-free survival (EFS) and other relevant end points for this patient population.

In our exclusive interview, Sekeres discussed the current unmet needs of patients with HR-MDS receiving HMAs, the potential utility of novel combinations in development, and the incorporation of other end points beyond OS in clinical trials.

Podcasts

that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays. 

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Publications

® Publications page showcases all of the exclusive content that appears in the twice-monthly print publication 

 Multiple print supplements that run in tandem with 

, including meeting reporters, priority reports, My Treatment Approach, and Year in Review publications, can all be found on this Publications page. 

Oncology Expert Insights

Sylvester Comprehensive Cancer Center, University of Miami

Cancer Centers

Partner

Emerging Treatments and Clinical Challenges in Myelodysplastic Syndromes: ASCO 2021 and EHA 2021 Updates

Supplements and Featured Publications

Dr. Sekeres discusses the current unmet needs of patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents, the potential utility of novel combinations in development, and the incorporation of other end points beyond overall survival in clinical trials.

Sekeres Previews Potential Combination Strategies in HR-MDS